All In Biotech

Drugs by condition

Drugs approved for cystic fibrosis

Brand-name prescription drugs and biologics whose FDA label lists cystic fibrosis as an approved use. Matched on the label phrases: "cystic fibrosis".

Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

18

Still marketed, NDA or BLA

Drug classes

4

Novel drugs

7

New molecular entities and new biologics

In development

15

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for cystic fibrosis.

  • Brinsupri (Brensocatib) · Insmed INC NovelBreakthrough therapyPriority reviewAug 12, 2025
  • Alyftrek (Deutivacaftor, Tezacaftor, Vanzacaftor Calcium) · Vertex Pharms INC NovelPriority reviewOrphanDec 20, 2024
  • Trikafta (Copackaged) (Elexacaftor, Ivacaftor, Tezacaftor, Ivacaftor) · Vertex Pharms INC Priority reviewOrphanApr 26, 2023
  • Trikafta (Copackaged) (Elexacaftor, Ivacaftor, Tezacaftor, Ivacaftor) · Vertex Pharms INC NovelBreakthrough therapyPriority reviewOrphanOct 21, 2019
  • Orkambi (Ivacaftor, Lumacaftor) · Vertex Pharms INC Breakthrough therapyPriority reviewOrphanAug 7, 2018

All approved drugs for cystic fibrosis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 60 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Cystic Fibrosis Transmembrane Conductance Regulator Potentiator (5)

  • Alyftrek Deutivacaftor, Tezacaftor, Vanzacaftor Calcium · Vertex Pharms INC · 2024
  • Orkambi Ivacaftor, Lumacaftor · Vertex Pharms INC · 2015
  • Kalydeco Ivacaftor · Vertex Pharms · 2012
  • Orkambi Ivacaftor, Lumacaftor · Vertex Pharms INC · 2018
  • Kalydeco Ivacaftor · Vertex Pharms INC · 2015

Aminoglycoside Antibacterial (4)

Recombinant Human Deoxyribonuclease 1 (1)

Class not listed in FDA's data (8)

Drugs in development for cystic fibrosis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • HSK31858Phase 33 trials

    Haisco Pharmaceutical Group Co., Ltd. · Non-cystic Fibrosis Bronchiectasis, Asthma Bronchiale, Bronchiectasis

  • VX-121D-IVA, CTP-656Phase 33 trials

    Vertex Pharmaceuticals · Cystic Fibrosis

  • GalvokimigUCB9741Phase 23 trials

    UCB · Chronic Obstructive Pulmonary Disease With Chronic Bronchitis, Atopic Dermatitis, Non-cystic Fibrosis Bronchiectasis

  • ANG003Phase 21 trial

    Anagram Therapeutics, Inc. · Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF)

  • ARCT-032Phase 21 trial

    Arcturus Therapeutics, Inc. · Cystic Fibrosis, CFTR Gene Mutation

  • BX004Combination of nebulized bacteriophages targeting Pseudomonas aeruginosaPhase 21 trial

    BiomX Ltd · Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)

  • CMTX-101Phase 21 trial

    Clarametyx Biosciences, Inc. · Persistent Infection, Cystic Fibrosis

  • CSL787Phase 21 trial

    CSL Behring · Non-cystic Fibrosis Bronchiectasis

  • ETD001Phase 21 trial

    Enterprise Therapeutics Ltd · Cystic Fibrosis

  • NHS7108Phase 21 trial

    Aimmune Nestlé Health Science US R&D, LLC · Exocrine Pancreatic Insufficiency (EPI), Cystic Fibrosis (CF), Pancreatic Enzyme Abnormality

  • RCT2100Phase 21 trial

    ReCode Therapeutics · Cystic Fibrosis

  • RESP302Phase 21 trial

    Thirty Respiratory Limited · Non-Cystic Fibrosis Bronchiectasis

  • RESP303Phase 21 trial

    Thirty Respiratory Limited · Non-Cystic Fibrosis Bronchiectasis

  • RSP-1502Phase 21 trial

    Respirion Pharmaceuticals Pty Ltd · Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa

  • SPL84Phase 21 trial

    SpliSense Ltd. · Cystic Fibrosis

More on cystic fibrosis: recruiting trials · published research

Related in respiratory: Pulmonary arterial hypertension · Asthma · COPD · Idiopathic pulmonary fibrosis · Allergies (allergic rhinitis)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.